연구성과로 돌아가기

2023 연구자 정보 (145 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Rizzardini, Giuliano
(Rizzardini, G)
Asst Fatebenefratelli Sacco, Milan, Italy

[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Roh, Yoon-Seok
(Roh, YS)
Chungbuk Natl Univ, Cheongju, South Korea

[JCR상위 4.5] ALPHA-1 ANTITRYPSIN/ PROTEINASE 3 IMBALANCE EXERTS PROTEOLYTIC REGULATION ON INTERLEUKIN-32 GAMMA TO PROMOTE NONALCOHOLIC STEATOHEPATITIS SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Rosenthal, Philip
(Rosenthal, P)
Univ Calif San Francisco, San Francisco, CA 94143 USA

[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Schwarz, Kathleen B.
(Schwarz, KB)
제1저자 Univ Calif San Diego, Rady Childrens Hosp San Diego, San Diego, CA 92103 USA

[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Seo, Yun Jee
(Seo, YJ)
Samsung Med Ctr, Inst Refractory Canc Res, Res Inst Future Med, Seoul, South Korea

[JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma SCIE 4.5 GENETICS & HEREDITY nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk;
Seol, Ho Jun
(Seol, HJ)
Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea
Sungkyunkwan Univ, Sch Med, Seoul, South Korea


[JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma SCIE 4.5 GENETICS & HEREDITY nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk;
Shalimar
(Shalimar)
All India Inst Med Sci, Delhi, India

[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Shin, Sang
(Shin, S)
Samsung Med Ctr, Inst Refractory Canc Res, Res Inst Future Med, Seoul, South Korea

[JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma SCIE 4.5 GENETICS & HEREDITY nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk;
Shin, Seung Kak
(Shin, SK)
Gachon Univ, Gil Med Ctr, Incheon, South Korea

[JCR상위 4.5] DECREASED RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH BESIFOVIR SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Sokal, Etienne M.
(Sokal, EM)
Clin Univ St Luc, Brussels, Belgium

[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Song, Jeongeun
(Song, J)
Daegu Catholic Univ, Sch Med, Gyongsan, South Korea
Daegu Catholic Univ, Sch Med, Daegu, South Korea


[JCR상위 4.5] AN ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTION OF HEPATOCELLULAR CARCINOMA DEVELOPMENT AFTER ORAL ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C☆
[JCR상위 4.5] HCC PREDICTION MODELS EFFECTIVELY ASSESS THE RISK OF HCC IN CHRONIC HEPATITIS C PATIENTS WITHOUT ADVANCED FIBROSIS AFTER ORAL ANTIVIRAL THERAPY: A MULTICENTER STUDY
SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Stepanova, Tatyana
(Stepanova, T)
Modern Med Clin, Traralgon, Australia
Modern Med Clin, Moscow, Russia


[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
Tamaki, Nobuharu
(Tamaki, N)
Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[JCR상위 4.5] Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net;
Tandon, Manish
(Tandon, M)
MV Hosp & Res Ctr, Lucknow, Uttar Pradesh, India

[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Theodore, Dickens
(Theodore, D)
GSK, Durham, NC USA
GSK, Stevenage, Herts, England


[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
페이지 이동: